CYP11B1

Across TCGA pan-cancer cohorts, CYP11B1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CYP11B1 data layer compared with 13 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CYP11B1 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CYP11B1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

UCEC, BLCA, and COAD are the cancer types where CYP11B1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	1.000	0.430	.004	34	view →
BLCA	OS	Median	IV	0.153	0.599	.018	9	view →
COAD	OS	Median	III,IV	0.208	0.791	.008	9	view →
PRAD	DFS	Median	All	0.589	0.935	.001	6	view →
LIHC	OS	Median	All	0.015	0.784	<.001	6	view →
SKCM	DFS	Median	II,III,IV	0.426	0.209	.011	5	view →
SARC	OS	Median	All	0.224	0.826	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CYP11B1–UCEC (DFS)

Open the UCEC breakdown →